CoreAge Rx 4PLAY review

You are not signed up to anything

This is the detail we would put first, because it is the one that separates this service from almost every competitor.

Auto-refill is opt-in after your first order, not opt-out. Nothing recurs unless you choose it. And if you would rather not have a plan at all, you can buy the same pack outright — the $114 advertised on the page is the subscription rate, and buying once costs roughly 5% more.

That matters because billing is where this entire category behaves worst. Several services we audited state no cancellation terms whatsoever; one requires twelve months paid up front and does not pro-rate refunds. Here the default is that nothing happens again until you say so — and a 5% premium to avoid a subscription entirely is about as fair as this gets.

The pricing is flat too: $114 a month against a stated $175, buying a five-vial pack of single doses — 10 mL in total, so about $23 a dose — with no dose-based markups, and you are refunded if a provider decides treatment is not clinically appropriate.

What is in it — we finally have the numbers

Four active ingredients in a 2 mL sublingual vial: sildenafil, tadalafil, vardenafil and apomorphine. Every previous version of this review had to stop there, because no quantity appears on any of the company's three landing pages.

We asked CoreAge Rx for the formulation and they sent it: the patient literature that ships with the medicine, issued by Foothills Professional Pharmacy of Tempe, Arizona, the compounding pharmacy that prepares it. It gives the strengths in full. Most companies in this comparison did not answer the same question.

This is more restrained than we expected, and it deserves saying plainly. No single ingredient is anywhere near its own ceiling. Add the three PDE5 inhibitors together and the total comes to roughly 98% of one maximum dose — about one full dose of this drug class, divided three ways, rather than three doses piled on top of each other.

For comparison, the two other stacked products in this comparison that do publish their doses come out at roughly 150% and 141% by the same arithmetic. On quantity, this is the most conservative of the three.

The pitch for the formulation is a real one: sildenafil comes on fast, tadalafil lasts long, vardenafil sits between them, and a sublingual preparation sidesteps the fixed off-the-shelf tablet. Reading the actual numbers, that is what the recipe looks like it is doing — a fast, broad opening dose with a small tail of the long-acting drug.

The objection that survives is not about quantity. The first three are all the same class doing the same job, and a third PDE5 inhibitor is not a third mechanism, it is more of the first. No guideline supports combining them and no FDA-approved product does it, so there is no trial telling you this beats one drug at a sensible dose. That remains true at a conservative total.

Apomorphine, the one that works differently

The fourth ingredient is the only one working differently — apomorphine is a dopamine agonist acting on the brain rather than the blood vessels. It has genuine history in this field, having been developed for ED and sold in Europe as Uprima. Here it is 2 mg per vial, which sits at the bottom of the 2 to 3 mg range that was studied for this use.

It was never approved in the United States, in part because of nausea and fainting. Fainting matters here: it is a blood-pressure effect, being added to three drugs that also lower blood pressure. The patient literature takes this seriously — it warns about dizziness and drowsiness, tells you not to drive until you know how it affects you, and says to be careful standing up quickly.

It is also the reason for the anti-nausea interaction above. The obvious remedy for a drug that causes nausea is an anti-sickness tablet, and the most commonly prescribed class of those is precisely the one you must not combine it with.

The safety information is among the best we found

Having criticised most of this category for hiding risk, we should be equally direct about a page that does not. This is the Important Safety Information block, in full:

“Do not use with nitrates or guanylate cyclase stimulators such as riociguat; the combination can cause a dangerous drop in blood pressure. Tell your provider if you take alpha-blockers or have cardiovascular disease, low blood pressure, or a history of priapism, stroke, or vision loss. Seek emergency care for an erection lasting more than four hours or sudden loss of vision or hearing. Common side effects include headache, flushing, nasal congestion, indigestion, and dizziness.”

Read what that does. It names the drug class and explains the consequence — the thing that actually changes behaviour. It names riociguat specifically. It flags alpha-blockers, which most pages skip. It covers the four-hour rule, sudden vision loss and sudden hearing loss. Of the thirty-seven pages we have audited, only a handful do as much, and this is the only combination product among them that also tells you it is compounded in the terms below.

The July rewrite went further still on the compounded disclosure, and it is now the fullest in this comparison: that compounded drugs are prepared under state board of pharmacy and USP standards, that they are not FDA-approved, that the FDA does not review them for safety, effectiveness or quality, that a compounded preparation is not a generic equivalent of and has not been shown to be therapeutically equivalent to the approved drug, and that certain ingredients may be prescribed off-label.

The July rewrite made a good page better

The page we audited has since been rebuilt, and it moved in the right direction — which is not the direction these pages usually move when a marketing team gets hold of them.

It now carries headline numbers: about ten minutes to onset, up to 36 hours of cover. Watch what it does with them. Both are footnoted as “based on published pharmacology of the active ingredients”, and the chart beside them is labelled “illustrative only … not measured patient data”. That is a company telling you its own headline figures describe the drug class rather than a trial of its product. We have not seen another page in this set do it.

It also added six named customer testimonials — and with them the disclosure almost nobody else provides: that these are not typical results, that reviews are solicited from all patients on the same terms and are not conditioned on being positive, and that any material connection is declared. Compare that with the services in this comparison that print five-star quotes and say nothing at all.

The compounded and billing disclosures grew in the same rewrite. Taken together, this is the most carefully disclosed marketing page in our set.

The one thing the rewrite did not add is the doses, and that is now in hand: the company supplied them on request, and tells us the landing pages are being updated to carry them. Having seen the figures, that will be a good day for the page — they are restrained numbers that support the product rather than embarrass it. We will re-audit and flip the check when they appear.

Three pages, three different stories

This is the part worth knowing as a buyer. CoreAge Rx runs at least three landing pages for the same product.

The one at coreagerx.com/product/4play/ carries no nitrate warning, no four-hour warning, no side effects and no cardiac prompt — and instead of the compounded-drug disclosure it uses the *dietary supplement* disclaimer, “these statements have not been evaluated by the Food and Drug Administration”, which is the wrong instrument for a prescription product.

The one at try.coreagerx.com/4play-sp has everything quoted above. We score this one, because that is where the paid search traffic goes — but a company that can write good safety copy should be using it on every page that sells the product.

The third, at try.coreagerx.com/comparison-1, is a sponsored advertorial — a first-person write-up that judges this product against two competitors we also review and finds for it every time. Advertorials of that kind usually arrive disguised as journalism. This one is labelled *Sponsored Content* at the top, states plainly that the author was compensated and that the publisher earns on the links, and carries the same full safety block as the main page. Our only complaint is the “offer may expire soon” beside the discount, which is the one piece of pressure the page it advertises does without.

Which page you see depends on which advert you click. The one that matters is the one the money goes through — and that is the page we score and the page we link to, comfortably the strongest of the three.

Who is actually prescribing it

A US board-certified physician reviews the questionnaire, and in some states a video consultation or live chat is required rather than optional — a real standard rather than a marketing line.

The corporate structure is disclosed openly too: the platform is operated separately from the medical entities that employ the prescribing clinicians. That arrangement is common in telehealth, and it is far better to see it stated plainly than to discover it in the small print — the brand is not the party making the clinical decision, and this company says so.

What to ask before your first dose

Nothing here should stop you buying it if it suits you. But this is a compounded prescription with four active drugs in it, and a few minutes of asking is worth it.

Confirm your own strengths. The figures above are the standard formulation from the pharmacy's own literature, but the company's position is that dosing is set per patient by the clinician rather than sold as a fixed tablet — which is the point of a compounded product. So your vial may differ. Ask what yours contains.

Tell them what you already keep at home. If you have sildenafil or tadalafil in a drawer, say so, so that nobody doubles you up by accident. This already contains three drugs from that class.

Mention anything you take for nausea, and any alpha-blocker for your prostate. The literature is explicit about both, and the intake is the right place to raise them.

One dose in 24 hours, and that is the limit unless your prescriber tells you otherwise. The literature states it plainly. With three PDE5 inhibitors in a vial, taking a second one because the first felt weak is the specific mistake to avoid.

On price, $114 a month — five doses, about $23 each — sits at the top of this comparison; a two-drug competitor sells at roughly $2 a pill. What the difference buys is real, though: compounding to your own prescription, a board-certified physician actually reviewing it, a refund if the answer is no, and no subscription tying you in. If those are the things you were worried about, this is where the money goes.

One honest caveat about who this suits. If you have never taken an ED medication at all, we would still say start with one drug at a proper dose — it is cheaper, better evidenced, and the result tells you something you can build on. Come back to a four-ingredient formulation once you know how you respond to a single one. How the single drugs compare.